Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1.
Yajima H, Anraku Y, Kaku Y, Kimura KT, Plianchaisuk A, Okumura K, Nakada-Nakura Y, Atarashi Y, Hemmi T, Kuroda D, Takahashi Y, Kita S, Sasaki J, Sumita H; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ito J, Maenaka K, Sato K, Hashiguchi T. Yajima H, et al. Among authors: hemmi t. Nat Commun. 2024 Oct 7;15(1):8574. doi: 10.1038/s41467-024-52808-2. Nat Commun. 2024. PMID: 39375326 Free PMC article.
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Hemmi T, Ainai A, Hashiguchi T, Tobiume M, Kanno T, Iwata-Yoshikawa N, Iida S, Sato Y, Miyamoto S, Ueno A, Sano K, Saito S, Shiwa-Sudo N, Nagata N, Tamura K, Suzuki R, Hasegawa H, Suzuki T. Hemmi T, et al. Vaccine. 2022 Sep 29;40(41):5892-5903. doi: 10.1016/j.vaccine.2022.08.049. Epub 2022 Aug 26. Vaccine. 2022. PMID: 36064667 Free PMC article.
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Ainai A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Maeda K, Fukushi S, Takahashi Y, Suzuki T. Miyamoto S, et al. Among authors: hemmi t. Med. 2022 Apr 8;3(4):249-261.e4. doi: 10.1016/j.medj.2022.02.006. Epub 2022 Mar 4. Med. 2022. PMID: 35261995 Free PMC article.
Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization.
Miyamoto S, Arashiro T, Ueno A, Kanno T, Saito S, Katano H, Iida S, Ainai A, Ozono S, Hemmi T, Hirata Y, Moriyama S, Kotaki R, Kinoshita H, Yamada S, Shinkai M, Fukushi S, Takahashi Y, Suzuki T. Miyamoto S, et al. Among authors: hemmi t. iScience. 2023 Feb 17;26(2):105969. doi: 10.1016/j.isci.2023.105969. Epub 2023 Jan 13. iScience. 2023. PMID: 36687316 Free PMC article.
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
Sonoyama T, Iwata S, Shinkai M, Iwata-Yoshikawa N, Shiwa-Sudo N, Hemmi T, Ainai A, Nagata N, Matsunaga N, Tada Y, Homma T, Omoto S, Yokokawa Shibata R, Igarashi K, Suzuki T, Hasegawa H, Ariyasu M. Sonoyama T, et al. Among authors: hemmi t. Vaccine. 2023 Mar 10;41(11):1834-1847. doi: 10.1016/j.vaccine.2022.12.025. Epub 2022 Dec 16. Vaccine. 2023. PMID: 36572603 Free PMC article. Clinical Trial.
49 results